Quantinuum plans to offer 21 million shares at $45–$50, targeting $1.05 billion in proceeds and a $12.7 billion valuation. The Broomfield company posted a Q1 net loss of $136.6 million on $5.2 million revenue, versus a $30.5 million loss on $19.1 million last year.
Quantinuum plans to market approximately 21 million shares in its US IPO at $45 to $50 each, aiming to raise $1.05 billion. Priced at the top end, this places the company’s market value at about $12.7 billion based on outstanding shares.
For the quarter ended March 31, Quantinuum reported a net loss of $136.6 million on $5.2 million in revenue, deepening from a $30.5 million loss on $19.1 million revenue in the year-ago period. The widened loss reflects continued R&D investment and scaling costs.
The company develops quantum computers designed to tackle complex tasks beyond classical processors, targeting sectors such as chemistry, machine learning, cybersecurity, finance and drug discovery. Leadership cites a roadmap to launch the first commercial-scale, fault-tolerant Apollo system by decade’s end.
Quantinuum is slated to receive $100 million from the Commerce Department’s quantum funding program, joining peers in a more than $2 billion package. Early collaborators include Amgen and Mitsui, supporting development and real-world testing of quantum platforms.
